<![CDATA[Neuraptive Therapeutics, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=35034>Wed, 15 Apr 2026 05:44:17 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair]]>https://www.newswire.co.kr/newsRead.php?no=1020198Sun, 05 Oct 2025 11:40:00 +0900<![CDATA[뉴랩티브 테라퓨틱스, 신경 손상 치료제 NTX-001 안전성 및 유효성 비교 평가 3상 임상시험에 첫 환자 등록 발표]]>https://www.newswire.co.kr/newsRead.php?no=1020199Sun, 05 Oct 2025 11:40:00 +0900<![CDATA[Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting]]>https://www.newswire.co.kr/newsRead.php?no=997160Fri, 20 Sep 2024 17:00:00 +0900<![CDATA[뉴랩티브 테라퓨틱스, NTX-001의 임상 2상 탑라인 중간 결과를 2024년 미국수부외과학회 연례회의에서 발표]]>https://www.newswire.co.kr/newsRead.php?no=997161Fri, 20 Sep 2024 17:00:00 +0900<![CDATA[Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair]]>https://www.newswire.co.kr/newsRead.php?no=996881Fri, 13 Sep 2024 13:40:00 +0900<![CDATA[뉴랩티브 테라퓨틱스, NTX-001에 대한 FDA 혁신 치료제 지정 획득 및 복구가 필요한 말초신경 손상 치료용 NTX-001의 진전 사항 업데이트]]>https://www.newswire.co.kr/newsRead.php?no=996883Fri, 13 Sep 2024 13:40:00 +0900<![CDATA[Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data]]>https://www.newswire.co.kr/newsRead.php?no=985902Thu, 14 Mar 2024 11:20:00 +0900<![CDATA[뉴랩티브 테라퓨틱스, 2상 임상시험 뉴로퓨즈 연구의 NTX-001에 대한 24주차 긍정적 데이터 발표로 앞서 공개된 12주 개념증명 데이터 강화]]>https://www.newswire.co.kr/newsRead.php?no=985903Thu, 14 Mar 2024 11:20:00 +0900<![CDATA[Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset]]>https://www.newswire.co.kr/newsRead.php?no=982667Tue, 16 Jan 2024 09:40:00 +0900<![CDATA[뉴랩티브 테라퓨틱스, 자사의 유망한 개발 자산이 FDA 희귀의약품으로 지정]]>https://www.newswire.co.kr/newsRead.php?no=982668Tue, 16 Jan 2024 09:40:00 +0900<![CDATA[Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves]]>https://www.newswire.co.kr/newsRead.php?no=982407Wed, 10 Jan 2024 13:20:00 +0900<![CDATA[뉴랩티브 세라퓨틱스, 절단된 말초 신경의 보조치료 위한 NTX-001의 NEUROFUSE 임상시험에서 개념 증명 달성]]>https://www.newswire.co.kr/newsRead.php?no=982408Wed, 10 Jan 2024 13:20:00 +0900<![CDATA[Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board]]>https://www.newswire.co.kr/newsRead.php?no=956012Fri, 18 Nov 2022 15:30:00 +0900<![CDATA[뉴랩티브 세라퓨틱스, 이사회 이사로 유명 경영인 로버트 R. 루폴로 박사 선임]]>https://www.newswire.co.kr/newsRead.php?no=956013Fri, 18 Nov 2022 15:30:00 +0900<![CDATA[Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair]]>https://www.newswire.co.kr/newsRead.php?no=954159Tue, 25 Oct 2022 14:55:00 +0900<![CDATA[뉴랩티브세라퓨틱스, 임원 인사 단행해 신경 복원 발전 뒷받침]]>https://www.newswire.co.kr/newsRead.php?no=954160Tue, 25 Oct 2022 14:55:00 +0900<![CDATA[Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma]]>https://www.newswire.co.kr/newsRead.php?no=948441Fri, 22 Jul 2022 13:45:00 +0900<![CDATA[뉴랩티브 세라퓨틱스, 안면 마비 예방·치료용 NTX-001 임상 2상 첫 환자 등록하고 외상 PNI용 NTX-001의 임상 2상 연구 결과 업데이트]]>https://www.newswire.co.kr/newsRead.php?no=948442Fri, 22 Jul 2022 13:45:00 +0900<![CDATA[뉴랩티브 세라퓨틱스, NTX-001 대한 임상연구계획(IND) FDA 승인 획득… 말초신경 손상 환자 치료 위한 새로운 접근 연구]]>https://www.newswire.co.kr/newsRead.php?no=904436Wed, 29 Apr 2020 18:08:16 +0900<![CDATA[Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries]]>https://www.newswire.co.kr/newsRead.php?no=904434Wed, 29 Apr 2020 18:02:17 +0900